At Europe’s largest cardiology conference in London, researchers reported on a drug that reduced complications from heart failure, improved heart structure and function, and even saved lives of people with Covid-19. The conference also featured a trial of the drug in kidney disease. Richard Pratley, a diabetes specialist, introduced the trial to the crowd. This drug was a focal point of the conference, showcasing its potential benefits across various conditions. This session highlighted the positive impact of the drug on heart health and its potential in treating other diseases, setting the stage for further research and development.
Source link
At Europe’s larget cardiology conference, Wegovy’s the word
